6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These findings have informed clinical practice guidelines and policy, which now recommend that SMBG not be used routinely in this group (21–26).”
In the citing paper
“While the drug manufacturer is currently offering a savings card program for some patients for whom pricing is a barrier, payor coverage for tirzepatide will likely be a barrier to patient use, especially before tirzepatide has been officially recognized as a standard of care in professional guidelines. 2”
From Tirzepatide: Clinical review of the twincretin injectable (2023) · cites this paper as [2]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“33% with metformin as initial pharmacotherapy) and in all-cause mortality (13% and 27%, respectively) (33).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Research works printed but not linked: 1
- Dicembrini, Impact of technology on glycemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion, Diabetes Obes Metab
Cited by
Items 701–800 of 846
Mankovskyi, G. B., Dzhun, Y. Y., Marushko, Y. Y., Saienko, Y. A., Rudenko, N. M., & Mankovsky, B. (2022) · Ukrainian journal of cardiovascular surgery · doi:10.30702/ujcvs/22.30(01)/md011-8388 · Cited by 1
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Agarwalla, A., Gruen, J., Peters, C. J., Sinnenberg, L. E., OWENS, A. T., & Reza, N. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.31
Nah, E., Cho, S., Park, H., Noh, D., Kwon, E., & Cho, H. (2022) · Healthcare · doi:10.3390/healthcare10050824 · Cited by 2
Effect of bee propolis as a hypoglycemic agent and diabetes control
Grosso, G. S., & Tangarife, M. P. O. (2021) · International Journal of Family & Community Medicine · doi:10.15406/ijfcm.2021.05.00249 · Cited by 1
Diabetes Control During Massachusetts Insurance Reform
Chen, M. T., Krzyszczyk, D., Brown, A. G. M., Kressin, N. R., Terrin, N. C., Hanchate, A. D., Suzukida, J., Kher, S., Price, L. L., LeClair, A. M., et al. (2021) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01046-z
Tung, B. N., Ton, M. D., & Hung, P. M. (2022) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v154i6.726
Berge, T. V. D., Biester, S., Biester, T., Buchmann, A.-K., Datz, N., Grosser, U., Kapitzke, K., Klusmeier, B., Remus, K., Reschke, F., et al. (2022) · Diabetes aktuell · doi:10.1055/a-1851-2883
Ramírez, J. E. P., Beltrán, J. S. U., & Palomeque, G. A. E. (2022) · Tesla Revista Científica · doi:10.55204/trc.v9789i8788.48
Dutta, S., Maulik, S. G., & Nayak, J. (2022) · PARIPEX-INDIAN JOURNAL OF RESEARCH · doi:10.36106/gjra/0200127
Assessment of Cognitive Function in Diabetic Patients – A Case-Control Study
Al-Tamimi, A. I., Aljirdabi, N. S., & Almosawi, S. (2022) · Journal of the Bahrain Medical Society · doi:10.26715/jbms.34_2022_2_2
Faster Insulin Aspart for Continuous Subcutaneous Insulin Infusion: Is It Worth It?
Rosinha, P. M. O., Teixeira, S., Vilaverde, J., & Cardoso, M. H. (2022) · Cureus · doi:10.7759/cureus.28422 · Cited by 2
Liên, T. T. B., & Vân, N. K. D. (2022) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v518i1.3365
Johnston, E. A., Roque, N. A., Cole, B. H., Flanagan, M., Kris‐Etherton, P. M., & Petersen, K. H. (2022) · Diabetology · doi:10.3390/diabetology3040038
Application of Continuous Glucose Monitoring Systems in Patients With Type 2 Diabetes Mellitus
(2022) · European Journal of Medicine · doi:10.13187/ejm.2022.1.12 · Cited by 1
Prattichizzo, F., & Ceriello, A. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00968-4
Milla, S. P., Malpartida, K. G., Burgos, R., Almeida, J. M. G., Matía‐Martín, P., París, A. S., Murillo, A. Z., Martínez, J. J. A., Fullana, A. A., Continente, A. J. C., et al. (2022) · Nutrición Hospitalaria · doi:10.20960/nh.04509
Malnutrition management of hospitalized patients with diabetes/hyperglycemia and heart failure
Murillo, A. Z., Chinchetru, M. A. J., Burgos, R., Almeida, J. M. G., Matía-Martín, P., Milla, S. P., París, A. S., Martínez, J. J. A., Fullana, A. A., Continente, A. J. C., et al. (2022) · Nutrición Hospitalaria · doi:10.20960/nh.04508
Geliebter, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-15353-2_7
Hussein, H. Q., Salih, A. M., & Merza, M. A. (2022) · Health Problems of Civilization · doi:10.5114/hpc.2022.122344
Daneshmand, M., Farzadfar, F., Jamshidi, H., Mortazavi, S. S., Shati, M., & Farjoo, M. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2505848/v1
Effects of Sheng-Mai Injection on Diabetes Mellitus: A Systematic Review and Meta-analysis
Yang, M., Hu, Z., & Yue, R. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230127121738 · Cited by 1
Latzig, D. L., Baynes, S. C., Feuerhake, T., & Gunsolus, I. L. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.02.001
ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ CÁC YẾU TỐ LIÊN QUAN CỦA BỆNH NHÂN ĐÁI THÁO ĐƯỜNG MANG THAI
Nguyễn, T. V. C., & Nguyễn, K. D. V. (2023) · Tạp chí Y học Việt Nam · doi:10.51298/vmj.v521i2.4042 · Cited by 1
He, Q., Hawkins, G. T., Park, C., Han, S., LaManna, J. B., & Ng, B. P. (2023) · Chronic Illness · doi:10.1177/17423953231158139
Glycaemic control and associated factors in adult patients with diabetes mellitus, South Sudan, 2021
Mogga, J. L. K., Loro, S., Gai, S., Anyit, M., Awu, R., Hadija, S., Aliti, J., Biriwo, L. S., & Ameh, D. (2023) · South Sudan Medical Journal · doi:10.4314/ssmj.v16i1.2
Stojanović, M., Pešić, M., Ilić, S., Deljanin-Ilić, M., & Ćirić, V. M. (2022) · AFMN Biomedicine · doi:10.5937/afmnai40-37498
Požar, H., Simin, D., & Požar, Č. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01194-4 · Cited by 1
“…6000 device: blood glucose (mmol/L and mg/dL) after fasting at least 8 h (prepran-dial) and 2 h after a meal (postprandial); glycosylated hemoglobin (A1C, % and mmol/mol) [18]; lipid profile (mmol/L and mg/dL), including total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglyceride [19].”
BackgroundGuo, L., Zhu, D., Chen, K., Xue, Y., Zhou, C. Y., Liu, P., Hu, Z., Gu, P., Zhang, W., Dong, H., et al. (2023) · doi:10.2196/preprints.47363
Focus on a special tool for postprandial glucose control: Ultra rapid lispro
Zhou, L., Qu, D., & Zhao, X. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2023-0508
Clinical Practice Guidelines, Evidence-Based Medicine and Diabetes
Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_23
Dong, T., Zhou, L., Gong, X., Ma, L., Bai, Y., & Chen, H. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.2622 · Cited by 1
“17 Multiple trials have suggested that patients with HbA1c ≥ 7% or DD ≥ 10 years were associated with a high risk of micro - vascular complications.”
Caracterización clínica y epidemiológica de pacientes con retinopatía diabética en primera consulta
Rosales, E. (2022) · Revista Arrupe · doi:10.36631/arrupe.2022.07.01
Gurger, S. S., Mittal, A., Goel, G., Mittal, A. K., & Kamboj, D. (2023) · Healthline · doi:10.51957/healthline_464_2022 · Cited by 1
“Glycemic control has been defined as achieving a target of fasting plasma glucose level of between 80 and 110 mg/dl, or glycosylated haemoglobin [7] (HbA1C) of 7.0%.”
InfluentialMoke-Bédji, L. O., N’Guessan, A. J.-L., Boyvin, L., Lohore, C., Bahi, G. A., Djaman, A. J., & Ankotché, A. (2023) · Advances in Biological Chemistry · doi:10.4236/abc.2023.133008
Cook, S. G., Gin, L. M., Taylor, A. K., Markert, R. J., & Hughes, J. G. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2022.09.013
Halim, S., Wijaya, D. A., Kurniawan, J., Hernani, A., Kusrini, H., Muslichah, M., & Firmansyah, Y. (2023) · MAHESA Malahayati Health Student Journal · doi:10.33024/mahesa.v3i10.11115 · Cited by 5
Longitudinal impact of COVID-19 pandemic on the utilization of hemoglobin A1c testing in outpatients
Zha, L., MacLeod, S. R., Love, T., Fortuna, R. J., & Zhang, Y. V. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117686
Glycemic control and dementia risk in patients aged above and below 75 years
Jung, H. H. (2024) · Diabetology International · doi:10.1007/s13340-023-00684-4
“The FBG 120 mg/dL was set as the reference (dashed lines) advanced age, the treatment target of blood glucose is commonly recommended to be relaxed in patients with limited life expectancy due to advanced age [20, 21].”
Ekpor, E., Akyirem, S., & Duodu, P. A. (2024) · medRxiv · doi:10.1101/2024.01.02.24300699
English, E. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch29 · Cited by 1
Goodman, D., Gonzalez-Rivas, J. P., Jaacks, L. M., Durán, M., Marulanda, M. I., Ugel, E., Chavarro, J. E., Danaei, G., & Nieto-Martínez, R. E. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002763
Daneshmand, M., Jamshidi, H., Farjoo, M. H., Malekpour, M. R., Ghasemi, E., Mortazavi, S. S., Shati, M., & Farzadfar, F. (2024) · Archives of Iranian Medicine · doi:10.34172/aim.2024.01
(2024) · Journal of Medical Clinical Case Reports · doi:10.47485//2767-5416.1062
“…improve the quality of life and psychological well-being of patients with DM. Cost-effectiveness has been reported with the use of CGM devices compared to SMBG. Current recommendations by the American Diabetes Association (ADA) about control of blood sugar using CGM are described in Figure 1 [13].”
MethodGroote, R. D., Lefever, E., Charleer, S., Donné, P., Block, C. E. M. D., Mathieu, C., & Gillard, P. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0616
“23,25,26”
Relationship Between Glucose, Prealbumin, and HbA1c in Hypoglycemic Patients
Palaz, B., İŞLER, Y., & Kaya, H. (2024) · Eurasian Journal of Critical Care · doi:10.55994/ejcc.1427619
Wu, X., Wang, R., Chen, J., Feng, G., Wang, X., Bai, R. N., Liang, X., Cao, B., Gong, C., Li, W., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14194 · Cited by 1
Swaney, E. E. K., McCombe, J., Donath, S. M., Cameron, F. J., & Australasian Diabetes Data Network Study Group (2024) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16531
Li, Y., Pan, T., Wang, L., Wang, Y., Gong, Y., Wang, G., & Zhang, Q. (2024) · Research Square · doi:10.21203/rs.3.rs-4337676/v1
Assessment of Medovaha Srotodushti in Madhumeha (Diabetes Mellitus) in Context with Hba1c
Rani, S. G. R. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr23820004751
Rivara, A. C., Russell, E. M., Carlson, J. C., Pomer, A., Naseri, T. K., Reupena, M. S., Manna, S. L., Viali, S., Minster, R. L., Weeks, D. E., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302643
Frequency of Hypoglycemia in Cirrhotic Patients Undergoing Endoscopy
Khan, D., Ullah, I., & yasir, M. (2024) · Cureus · doi:10.7759/cureus.62920 · Cited by 2
“Hypoglycemia, defined as a blood glucose level of less than 70 mg per dl is not uncommon in cirrhotic patients [4].”
Phú, N. K. T. P. N. K. T., Hoang, L. V., Ngân, L. H. K. N. L. H. K., Hậu, P. V., & Trí, T. C. T. T. C. (2024) · TẠP CHÍ KHOA HỌC TRƯỜNG ĐẠI HỌC QUỐC TẾ HỒNG BÀNG · doi:10.59294/hiujs.29.2024.608
Takebayashi, K., Yamauchi, M., Hara, K., Tsuchiya, T., & Hashimoto, K. (2024) · Cureus · doi:10.7759/cureus.64444
“Therefore, HbA1c is now an established marker of diagnosis, long-term glycemic control, and the risk of the progression of complications of diabetes [3,4].”
BackgroundPCOS – The Importance of Diet, Physical Activity, and Other Non-Pharmacological Methods in Treatment
Turek, M., Wojciechowska, K., Jaroń, A., Jastrzębska, K., Wiklińska, A., Witkowska, M., Skotnicka, J., Błaszczak, K., Borkowski, A., & Sawicki, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.19.53833 · Cited by 1
Clinical Utility of Serum C-Peptide Concentration for Hospitalized Patients with Hyperglycemia
Costa, D. N., Kudva, Y. C., Jensen, M. D., & Shah, P. R. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0246
Sanjeevani, M., Alex, M., Sreedharan, D. P., Vinay, B. C., Supriya, P. S., Bhandari, R., & Kolar, R. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01397-3
“Further, FBS as per 2021 ADA recommendations for glycemic control, is 80–130 mg/dL [12].”
Calderón, B., Soto, M., & Beltré, A. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100203 · Cited by 2
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_7
Study of Serum Levels of Copper, Iron and Zinc in Type II Diabetes Mellitus Patients
Dutt, R. K. (2024) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i4s.4751
A network analysis to explore illness perceptions in Black adults with type 2 diabetes
Wen, M., Zou, T., Bolt, D. M., & Shiyanbola, O. O. (2024) · British Journal of Health Psychology · doi:10.1111/bjhp.12775 · Cited by 1
Zaleckytė, D., & Žilinskienė, J. (2024) · Baltic Journal of Sport and Health Sciences · doi:10.33607/bjshs.v2i133.1544
Rural Culture and Diabetes Self-Management Beliefs, Behaviors, and Health Outcomes
Pullyblank, K. L. (2025) · Nursing Research · doi:10.1097/nnr.0000000000000806
Yao, H., Chen, Y., Dong, Y., Zhang, G., Luo, W., Chen, J., Chen, Y.-F., & Guo, J. (2025) · Nursing in Critical Care · doi:10.1111/nicc.13245
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch03
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch04
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch5
Glycemic Goals and Assessment of Glycemia
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch02
Lee, W., Chen, H., Fang, C.-Y., Tsai, Y., Hsieh, Y.-Y., Chen, T., Fang, Y., Wu, P., Fang, H., & Liu, P. (2025) · Current Vascular Pharmacology · doi:10.2174/0115701611322555250219111038
“%) may also be beneficial for patients experiencing microvascular or macrovascular complications [18].”
Romagnoli, A., Savoia, M., Papini, G., Caprodossi, A., & Bartolini, F. (2025) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2024-004383 · Cited by 2
Foudjo, B. U. S., Aphrodite, C. T., Ngnie‐Teta, I., Kenmoe, J., Latsap, D., Navti, L. K., & Nantia, E. A. (2025) · International Journal of Diabetes and Endocrinology · doi:10.11648/j.ijde.20251001.11
Çok Yüksek HbA1c Değerlerinin Diyabetik Komplikasyonlarla İlişkisinin Değerlendirilmesi
Urakçı, Z., Tuzcu, A. K., & Pekkolay, Z. (2025) · Dicle Medical Journal / Dicle Tip Dergisi · doi:10.5798/dicletip.1657582
Carcone, A. I., Baskar, D., Mahmood, A., MacDonell, K. K., Eggly, S. S., Ghosh, S., Buggs‐Saxton, C., Ondersma, S. J., & Ellis, D. A. (2025) · doi:10.2196/preprints.75623
Ambreen, S., Wari, R., Tariq, M., Qayyum, F., Zahra, F. T., & Saadat, R. L. (2025) · Biological and Clinical Sciences Research Journal · doi:10.54112/bcsrj.v6i2.1589
HbA1c reduction strategies: An overview of pharmacological interventions
Upadhye, K. S., Patidar, H., Bamnia, N., & Yadav, N. K. (2025) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_72_24 · Cited by 2
Changes in Glucose level During Chemotherapy Treatment in Patients With Stage I–IV Breast Cancer
Schnell, P., Kassem, M., Miah, A., Ramaswamy, B., Williams, N. O., Cherian, M. M., Stover, D. G., Gatti-Mays, M. E., Pariser, A. C., Wesolowski, R., et al. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.05.021
Wang, Z., Lavikainen, P., Wikström, K., & Laatikainen, T. K. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01763-2 · Cited by 3
“An HbA1c level of 53 mmol/mol was defined as the general treatment target according to both the Finnish Current Care Guidelines and the American Diabetes Association recommendations for managing T2D [5, 17].”
Nath, B., Aggarwal, S., Parveen, N., Chittawar, S., Khandelwal, D., & Kalra, S. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01520-y
Shilov, V. V., Litvyak, V. V., Zhurnia, A. A., Росляков, Ю. Ф., Витальевна, О. Т., & Mazur, A. M. (2025) · New Technologies · doi:10.47370/2072-0920-2025-21-2-114-139
Guyo, K., Mekonnen, M. M., Getaye, A., & Hailu, D. (2025) · Research Square · doi:10.21203/rs.3.rs-6946170/v1
Shah, S. A., Ahmad, S., Bilal, M., Khan, Y. N., Ullah, S., & Khan, M. T. (2025) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v6i7.3219
Hilmawati, F., & Karuniawati, H. (2025) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v8i3.1008
Sawyer, L., Suchy‐Dicey, A. M., Nelson, L. A., Sarche, M. C., Reese, J. A., Cole, S. A., Sitlani, C. M., Umans, J. G., & Fretts, A. M. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0007
Management of patients with asymptomatic carotid disease
Kim, Y. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13865-2.00008-1
Abrahim, R. Y., Gudu, A., Abdi, D., Nuredin, K., Alemu, S., Azene, K., Lemma, B., & Getachew, O. (2025) · Science Frontiers · doi:10.11648/j.sf.20250603.12
Mancillas-Berrelleza, L. A., Miranda-Félix, P. E., Valtier, M. C. G., Ortiz-Félix, R. E., & Leyva-Perea, J. J. (2025) · Población y Salud en Mesoamérica · doi:10.15517/dx63hy98
Li, C., He, D., Yang, C., Zhang, L., & Pop‐Busui, R. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112909
Patkar, N. V., & Panikar, V. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20253147
Rebreathing‐induced hypoxemia improves glucose tolerance in adults with type 2 diabetes
Zhao, J., Guei, J. G., & Lalande, S. (2025) · Physiological Reports · doi:10.14814/phy2.70596
“…nutrition, and physical activity to treat type 2 diabetes, almost half of U.S. adults diagnosed with diabetes do not achieve the recommended HbA1c of less than 7% (American Diabetes Association, 2021; American Diabetes Association, 2025; Centers for Disease Control and Prevention, 2024).”
Kim, S., Kang, M., Park, D., Kim, G., & Kim, J. H. (2025) · BMC Public Health · doi:10.1186/s12889-025-24617-9 · Cited by 1
Glucosa y hemoglobina glicosilada como marcadores tempranos del síndrome metabólico
Jaramillo, G. J. A., & Flores, X. D. R. R. (2025) · Esprint Investigación · doi:10.61347/ei.v4i3.188 · Cited by 1
Belhedi, M., Lazzem, W., Bacha, O., Ba, A., Dabboubi, R., & Chouaieb, S. (2025) · Electrophoresis · doi:10.1002/elps.70064
Fløde, M., Hermann, M., Igland, J., Hernar, I., Sigurðardóttir, Á. K., Søfteland, E. W., Åsberg, A., Jenssen, T. G., & Haugstvedt, A. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06732-9 · Cited by 1
“National and international guidelines provide limited recommendations on managing glucose regulation in older people with diabetes, often only suggesting a slightly higher HbA1c to prevent hypoglycaemia [5, 33].”
Fløde, M., Hermann, M., Haugstvedt, A., Søfteland, E., Igland, J., Åsberg, A., Jenssen, T. G., & Graue, M. (2023) · Figshare · doi:10.6084/m9.figshare.24286550
Kong, Y. W., Yuan, C. Y., Kiburg, K., Brown, K., Trawley, S. L., Partovi, A., ROEM, K. L., Harrison, N., Fourlanos, S., Ekinci, E. I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24277196
Peprah, E. B., Jahan, Y., Danso‐Appiah, A., Abdul-Samed, A.-B., Mirzoev, T. N., Antwi, E., Balabanova, D., & Agyepong, I. A. (2024) · Figshare · doi:10.6084/m9.figshare.26945544
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S73-S84
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4236126199
- Cited by
- 847
- References
- 118
- Citations by year
- 2026: 43 · 2025: 80 · 2024: 115 · 2023: 156 · 2022: 265 · 2021: 187 · 2020: 1
- FWCI
- 23.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic targets, diabetes management, clinical guidelines, quality of care, level of evidence, treatment goals
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.